Tara Renée Heitner Hansen
Founder chez Abarceo AB
Profil
Tara Renée Heitner Hansen is the founder of Heitner Biopharm Consultation (founded in 2014) and Abarceo AB (founded in 2017), where she holds the title of Chief Executive Officer & Director.
She currently holds director positions at TikoMed AB, Nordic Pharma Licensing Group, and Bainan Biotech.
Her former positions include Chief Executive Officer at iSD Immunotech ApS (2018-2021) and Chief Executive Officer at Cyxone AB (2020-2022).
Dr. Heitner Hansen holds a doctorate from McGill University and an MBA from the Technical University of Denmark.
Postes actifs de Tara Renée Heitner Hansen
| Sociétés | Poste | Début |
|---|---|---|
Abarceo AB
 Abarceo AB Miscellaneous Commercial ServicesCommercial Services Abarceo AB develops novel therapeutics for type-2 diabetes. It identifies a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce insulin naturally. The company was founded by Tara Heitner, Claes Wollheim, and Albert Salehi in December 2017 and is headquartered in Malmo, Sweden. | Founder | 01/12/2017 |
| Nordic Pharma Licensing Group | Director/Board Member | - |
| Bainan Biotech | Director/Board Member | - |
TikoMed AB
 TikoMed AB Pharmaceuticals: MajorHealth Technology TikoMed AB is a Swedish pharmaceutical company that develops pharmaceutical products. The private company is based in Viken, Sweden. The company was founded by Adam Bruce, Lars Bruce. Anders Kristensson has been the CEO of the company since 2018. | Director/Board Member | - |
Anciens postes connus de Tara Renée Heitner Hansen
| Sociétés | Poste | Fin |
|---|---|---|
| CYXONE AB | Chief Executive Officer | 20/06/2022 |
iSD Immunotech ApS
 iSD Immunotech ApS BiotechnologyHealth Technology iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark. | Chief Executive Officer | - |
| Heitner Biopharm Consultation | Founder | - |
Formation de Tara Renée Heitner Hansen
| McGill University | Doctorate Degree |
| Technical University of Denmark | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CYXONE AB | Health Technology |
| Entreprise privées | 6 |
|---|---|
TikoMed AB
TikoMed AB Pharmaceuticals: MajorHealth Technology TikoMed AB is a Swedish pharmaceutical company that develops pharmaceutical products. The private company is based in Viken, Sweden. The company was founded by Adam Bruce, Lars Bruce. Anders Kristensson has been the CEO of the company since 2018. | Health Technology |
iSD Immunotech ApS
iSD Immunotech ApS BiotechnologyHealth Technology iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark. | Health Technology |
| Nordic Pharma Licensing Group | |
Abarceo AB
Abarceo AB Miscellaneous Commercial ServicesCommercial Services Abarceo AB develops novel therapeutics for type-2 diabetes. It identifies a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce insulin naturally. The company was founded by Tara Heitner, Claes Wollheim, and Albert Salehi in December 2017 and is headquartered in Malmo, Sweden. | Commercial Services |
| Heitner Biopharm Consultation | |
| Bainan Biotech |
